Enumeral Biomedical (ENUM) 1.0800 $ENUM
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.95 (-0.01), MRK: 57.46 (+0.25)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 57.46 (+0.25)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
Enumeral Appoints Robert L. Van Nostrand to its Board of Directors
Business Wire - Thu Dec 04, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it has appointed Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. OSI Pharmaceuticals, prior to its acquisition by Astellas Pharma, was a public company that, along with its partner Genentech, developed and commercialized the oncology drug, Tarceva(R).
Enumeral Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 3:35PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, today reported its financial results for the three and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.
Enumeral Appoints Isabel Chiu, Ph.D., as Vice President of Translational and Clinical Sciences
Business Wire - Tue Oct 21, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals.
Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer
Business Wire - Mon Sep 15, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies.
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral" (formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral.
TINY: 2.95 (-0.01)
Enumeral Biomedical Raises $21.5 Million from New and Current Investors, Begins Public Trading
Business Wire - Mon Aug 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" today announced the completion of a merger between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral has closed on $21.5 million in a private placement financing. Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "ENUM."
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.95 (-0.01), MRK: 57.46 (+0.25)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 57.46 (+0.25)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
Enumeral Appoints Robert L. Van Nostrand to its Board of Directors
Business Wire - Thu Dec 04, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it has appointed Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. OSI Pharmaceuticals, prior to its acquisition by Astellas Pharma, was a public company that, along with its partner Genentech, developed and commercialized the oncology drug, Tarceva(R).
Enumeral Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 3:35PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, today reported its financial results for the three and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. Enumeral Appoints Isabel Chiu, Ph.D., as Vice President of Translational and Clinical Sciences
Business Wire - Tue Oct 21, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals.
Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer
Business Wire - Mon Sep 15, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies.
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral"
(formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral. TINY: 2.95 (-0.01)
Enumeral Biomedical Raises $21.5 Million from New and Current Investors, Begins Public Trading
Business Wire - Mon Aug 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral"
today announced the completion of a merger between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral has closed on $21.5 million in a private placement financing. Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "ENUM." 
